Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Inclusion Criteria: * Age 18 years or older * Histologically or cytologically confirmed pancreatic adenocarcinoma. Must have locally advanced, recurrent, or metastatic disease ineligible for curative intent treatment(s) and eligible for first line systemic treatment. * Must have radiologic imaging with a computed tomography (CT) scan or magnetic resonance imaging (MRI) within 22 days of study entry * Must have at least one measurable lesion according to RECIST 1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Adequate gastrointestinal (GI), bone marrow, liver and kidney function * Life expectancy minimum of \> 12 weeks * Adequate recovery from surgery to Grade 1 or baseline with at least 28 days from time of major surgery Exclusion Criteria: * Received last dose of chemotherapy (neoadjuvant or adjuvant), surgery, or radiation treatment with curative intent within 6 months prior to study entry * Islet-cell neoplasms * Prior malignancy within the past 3 years except adequately treated basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix, breast or melanoma * Symptomatic uncontrolled central nervous system (CNS) metastasis or brain metastases unless adequately treated and controlled * Evidence of clinically significant third spacing (e.g. pleural effusion, ascites, anasarca, etc.) within 28 days prior to study entry * Serious active infection requiring IV antibiotics and/or hospitalization at study entry * Active human immune deficiency (HIV) syndrome, hepatitis B, hepatitis C, or other active viral illness